Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Safety and Efficacy of the ANTHEM™ CR Total Knee System

A legfontosabb adatok

Ki végzi
Smith & Nephew Pte Ltd
Hol
Dél-afrikai Köztársaság, Dél-Korea, India és Olaszország8 helyszín, 4 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
153 fő vett részt
Kezdés
2018. nov. 23.
Várható befejezés
2034. aug. 1.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • ANTHEM™ CR Total Knee System
A regiszteradat frissítve
2026. március 10.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject is a candidate for primary total knee arthroplasty due to degenerative joint disease
  • Subject is willing to sign and date an EC-approved consent form
  • Subject has posterior cruciate ligament and all collateral ligaments intact in the index joint
  • Subject is 18 to 75 years old at time of inclusion
  • Subject plans to be available through ten (10) years postoperative follow-up
  • Subject agrees to follow the study protocol
  • Subject has achieved skeletal maturity as deemed by enrolling investigator

Ki nem vehet részt

  • Subject would receive the ANTHEM™ CR Total Knee System on the affected knee as a revision for a previously failed (TKA) or unicondylar knee arthroplasty (UKA)
  • Subject received TKA on the contralateral knee as a revision for a previously failed TKA or UKA
  • Subject has an active infection or sepsis (treated or untreated) or previous intra-articular infections
  • Subject has contralateral lower extremity condition causing abnormal ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture)
  • Subject has a history of patellar fracture, patellectomy, or patello-femoral Instability
  • Inadequate bone stock which would make the procedure unjustifiable including but not limited to: severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia as deemed by the enrolling investigator
  • Subject has collateral ligament insufficiency
  • Subject has presence of malignant tumor, either primary or metastatic, or benign tumor on leg with the knee to be treated
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study, including mental illness, mental retardation, drug or alcohol abuse
  • Subject has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes mellitus [i.e. not under treatment with oral/injectable medications to control blood glucose levels], fibromyalgia, moderate to severe renal insufficiency or neuromuscular disease)
  • Subject has inflammatory arthritis
  • Subject possesses a contralateral or ipsilateral revision hip arthroplasty
  • Subject has ipsilateral hip arthritis resulting in flexion contracture
  • Subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:; Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary TKA or UKA
  • Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures
  • Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1
  • Any subject that meets the definition of a Vulnerable Subject per ISO14155:2011: individual whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate

Hol van ez a vizsgálat?

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This clinical study will evaluate the short-term (1- and 2-year) and medium term (5-year) safety and performance of the ANTHEM™ CR Total Knee System in patients with non-inflammatory degenerative joint disease of the knee requiring total knee replacement. Clinical, radiographic, Health Economic Outcomes and safety outcomes will be evaluated.

A vizsgált kezelések

  • ANTHEM™ CR Total Knee System

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicentre, Cohort Study Assessing the Safety and Efficacy of the ANTHEM™ CR Total Knee System in Patients Following a Total Knee Arthroplasty
A regiszteradat frissítve
2026. március 10.